Cell Cycle



Items 1 to 50 of 170 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction
Catalog No. Product Name Application Product Information
A15038

CCT241533 hydrochloride

Chk2 inhibitor
CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM.
A15550

CCT244747

CHK1 inhibitor
CCT244747 is a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor with potential anticancer activity,
A15480 SALE

SB 218078

Chk1 Inhibitor
SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively)
A15863

PD0166285

Wee1 inhibitor
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
A13684 SALE

LY2606368

Chk1 inhibitor
LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
A14178

GNE-900

Chk1 inhibitor
GNE-900 is an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor.
A13575 SALE

BML-277

Chk2 Inhibitor
BML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
A12703 SALE

SCH900776 (S-isomer)

CHK1 Inhibitor
SCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
A11520 SALE

PF 477736

Chk Inhibitor
PF 477736 is a selective checkpoint kinase 1 (Chk1) inhibitor (Ki values are 0.49 and 47 nM for Chk1 and Chk2 respectively).
A11167 SALE

SCH 900776 (MK-8776)

Chk1 inhibitor

SCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. It specifically binds to and inhibits Chk1, which may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases to undergo DNA repair prior to entry into mitosis; tumor cells may thus be sensitized to the DNA-damaging effects of ionizing radiation and alkylating chemotherapeutic agents.

A11108

CCT241533

Chk2 inhibitor
CCT241533 is a potent and selective Inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
A11046 SALE

CHIR-124

CHK Inhibitor
CHIR-124 is a novel and potent Chk1 inhibitor (IC50: 0.32 nM and 697 nM for Chk1 and Chk2 respectively).
A11036 SALE

LY2603618 (IC-83)

Chk inhibitor
LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.
A10113 SALE

AZD7762

Chk1 & Chk2 inhibitor
AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor that drives checkpoint abrogation and potentiates DNA-targeted therapies.
A15517 SALE

Purvalanol A

CDK inhibitor
Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor. IC50 values are 4, 70, 35, 850 and 75 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.
A15196

NVP-LCQ195

CDK inhibitor
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
A15485

AG-024322

CDK inhibitor
AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models.
A15767

NU2058

CDK inhibitor
NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1.
A15054

CVT-313

CDK2 Inhibitor
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
A14025

AMG-925

Dual FLT3/CDK4 inhibitor
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
A14273

LDC000067

CDK inhibitor
LDC000067 is a highly selective CDK9 inhibitor .
A13549 SALE

LEE011 (Ribociclib)

CDK4/6 inhibitor
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
A13547 SALE

P276-00

CDK Inhibitor
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
A13677 SALE

BMS-863233 (XL-413)

CDK inhibitor
BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
A12989 SALE

LY2835219 (abemaciclib)

CDK4/6 inhibitor
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
A14414

CA-224

CDK4 inhibitor
CA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
A13811 SALE

PD 0332991 Isethionate

CDK4/6 inhibitor
PD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
A14437 SALE

Ro 3306

CDK1 inhibitor
Ro 3306 is an ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively).
A13550 SALE

PHA690509

CDK inhibitor
PHA-690509 is a ATP-competitive CDK inhibitor.
A14392

Voruciclib

CDK inhibitor
Voruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A14318 SALE

SU9516

CDK2 inhibitor
SU9516 is a potent, selective cdk2 inhibitor. It inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest.
A14297

ML167

Clk4 inhibitor
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor
A14136

NU6027

ATR/CDK inhibito
NU6027 is a potent inhibitor of cellular ATR activity (IC(50)=6.7 μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.
A11962 SALE

TG-02 (SB1317)

FLT3 inhibitor
TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.
A14192 SALE

THZ1

CDK7 Inhibitor
THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM
A13506

AZD5597

CDK inhibitor
AZD5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.
A13524

NSC 663284

Cdc25 inhibitor
NSC 663284 is a potent, cell-permeable, and irreversible inhibitor of all Cdc25 isoforms, with preference for Cdc25A (IC50 = 29, 95, and 89 nM for Cdc25A, Cdc25B2, and Cdc25C, respectively).
A15039

CDK9 inhibitor 2

CDK9 inhibitor
CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
A16386

LY2835219 methanesulfonate

CDK4/6 inhibitor
LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
A16325

LY-3177833

CDC7 inhibitor
LY-3177833 is a potent and selective inhibitor of CDC7 (Cell Division Cycle 7-related Protein Kinase).
A15942

Bohemine

CDK inhibitor
Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 ,M.
A15889 SALE

K03861

CDK inhibitor
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
A14427

Palbociclib

CDK inhibitor
Palbociclib is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A12584

ON123300

CDK4 inhibitor‎
ON123300 is a potent multikinase inhibitor and may be potential useful for brain tumor chemotherapy. ON123300 strongly inhibits Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as ??-type platelet-derived growth factor receptor (PDGFR??).
A13130

RGB-286638

CDK inhibitor
RGB-286638 is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
A15823 SALE

LY2857785

CDK9 inhibitor
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
A12494

NG52

Cell cycle-regulating kinase inhibitor
NG52 is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase, Cdc28p (IC50 = 7 _mu_M), and the related Pho85p kinase (IC50 = 2 _mu_M).
A15005

AT7519 trifluoroacetate

CDK inhibitor
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM, less potent to CDK3 and little active to CDK7.
A13721 SALE

TG003

Clk inhibitor
TG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
A10701 SALE

PD 0332991 HCl (Palbociclib)

CDK 4/6 inhibitor
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.

Items 1 to 50 of 170 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction